FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new pyrido[2,3-b]pyrazine derivatives of general formula 
(I), wherein radicals and symbols are specified in the patent claim. The given compounds inhibit the enzymes ERK, ERK1, ERK2, PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p.
EFFECT: invention refers to a pharmaceutical composition to be used for preparing the drugs applicable first for treating malignant and other diseases implying the pathological cell proliferation.
10 cl, 3 tbl, 66 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TETRAHYDROCARBAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC AGENT THEREOF, METHOD OF TREATING AND/OR PREVENTING PHYSIOLOGICAL AND/OR PATHOLOGICAL CONDITIONS MEDIATED BY LHRH RECEPTOR BY ABOVE DERIVATIVES | 2008 |
|
RU2497806C9 |
| PYRIDO[2,3-b]PYRAZINE DERIVATIVES, MEDICINE FOR TREATMENT OF DISEASES OR ABNORMALITIES CAUSED BY MISDIRECTED CELLULAR SIGNAL TRANSDUCTION PROCESSES, METHOD OF MEDICINE OBTAINING | 2004 |
|
RU2330851C9 |
| NOVEL PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLIN-DEPENDANT KINASE | 2003 |
|
RU2380369C9 |
| CONJUGATES OF DISORAZOL, BASED PHARMACEUTICAL COMPOSITIONS, SAID CONJUGATES FOR PREPARING DRUG, KIT AND METHOD FOR PREPARING THEM | 2007 |
|
RU2473562C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
| NOVEL HETEROCYCLIC COMPOUNDS AS BRD4 INHIBITORS | 2016 |
|
RU2721120C2 |
| METHOD OF TREATMENT OR PREVENTION OF PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS MEDIATED BY GROWTH HORMONE SECRETION STIMULATING RECEPTORS, TRIAZOLE AND BASED PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2415134C9 |
| N4-PHENYLQUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS RECEPTOR TYROSINE KINASE TYPE ERBB INIHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | 2006 |
|
RU2428421C2 |
| INHIBITORS OF TYPE ErbB INHIBITORS | 2006 |
|
RU2592703C9 |
| 3,4-DISUBSTITUTED CYCLOBUTENE-1,2-DIONES AS LIGANDS OF CXC-CHEMOKINE RECEPTOR | 2002 |
|
RU2344123C9 |
